Dr. Srinivasan Kellathur is currently Director, Advanced Therapy Products Branch at Singapore Health Sciences Authority where his work involves policy reviews, drafting of regulations and guidelines, and marketing authorisation of cell, tissue and gene therapy products. He is also the Adjunct Assistant Professor at the Duke-NUS Centre of Regulatory Excellence. He is a co-lead for the regulatory convergence initiatives for advanced therapy products priority work area under the auspices of APEC regulatory harmonization steering committee. Srini sits on several national and international committees. He holds PhD from National University of Singapore and his post-doctoral research was from the Johns Hopkins University School of Medicine.